These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 20943719)
1. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719 [TBL] [Abstract][Full Text] [Related]
2. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946 [TBL] [Abstract][Full Text] [Related]
4. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Carlomagno F; Vitagliano D; Guida T; Ciardiello F; Tortora G; Vecchio G; Ryan AJ; Fontanini G; Fusco A; Santoro M Cancer Res; 2002 Dec; 62(24):7284-90. PubMed ID: 12499271 [TBL] [Abstract][Full Text] [Related]
5. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Vidal M; Wells S; Ryan A; Cagan R Cancer Res; 2005 May; 65(9):3538-41. PubMed ID: 15867345 [TBL] [Abstract][Full Text] [Related]
6. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447 [TBL] [Abstract][Full Text] [Related]
7. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. Verbeek HH; Alves MM; de Groot JW; Osinga J; Plukker JT; Links TP; Hofstra RM J Clin Endocrinol Metab; 2011 Jun; 96(6):E991-5. PubMed ID: 21470995 [TBL] [Abstract][Full Text] [Related]
8. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity. Zhu W; Hai T; Ye L; Cote GJ J Clin Endocrinol Metab; 2010 Jan; 95(1):439-44. PubMed ID: 19897677 [TBL] [Abstract][Full Text] [Related]
9. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464 [TBL] [Abstract][Full Text] [Related]
10. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells. Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157 [TBL] [Abstract][Full Text] [Related]
11. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Sarkar S; Mazumdar A; Dash R; Sarkar D; Fisher PB; Mandal M Cancer Biol Ther; 2010 Apr; 9(8):592-603. PubMed ID: 20139705 [TBL] [Abstract][Full Text] [Related]
12. AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines. Couto JP; Almeida A; Daly L; Sobrinho-Simões M; Bromberg JF; Soares P PLoS One; 2012; 7(10):e46869. PubMed ID: 23056499 [TBL] [Abstract][Full Text] [Related]
13. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Carlomagno F; Guida T; Anaganti S; Provitera L; Kjaer S; McDonald NQ; Ryan AJ; Santoro M Endocr Relat Cancer; 2009 Mar; 16(1):233-41. PubMed ID: 19029224 [TBL] [Abstract][Full Text] [Related]
14. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698 [TBL] [Abstract][Full Text] [Related]
15. Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. Shen J; Zheng H; Ruan J; Fang W; Li A; Tian G; Niu X; Luo S; Zhao P Br J Cancer; 2013 Jul; 109(1):164-71. PubMed ID: 23799852 [TBL] [Abstract][Full Text] [Related]
16. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. Carlomagno F; Santoro M J Chemother; 2004 Nov; 16 Suppl 4():49-51. PubMed ID: 15693160 [TBL] [Abstract][Full Text] [Related]
17. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Almeida MQ; Hoff AO Curr Opin Oncol; 2012 May; 24(3):229-34. PubMed ID: 22343387 [TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431 [TBL] [Abstract][Full Text] [Related]
20. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]